摘要
【目的】探讨肺癌患者外周血血小板计数与临床疗效的相关性。【方法】696例肺癌患者，按照各年龄段分为31～39岁24例、40～49岁153例、50～59岁222例、60岁以上297例。其中鳞癌280例、腺癌203例、小细胞癌151例、未分化癌62例；Ⅰ＋Ⅱ期43例、Ⅲa期64例、Ⅲb期412例、Ⅳ期177例；有转移组451例、无转移组245例；按照临床疗效将患者分为有效组561例、无效组135例。比较上述各组间患者外周血血小板增多率分布情况。【结果】肺癌患者血小板增多发生率为30．75％，以老年人血小板增高为主。血小板增多率在不同年龄组相比较差异具有显著性（P〈0．05），不同组织学类型相比较差异无显著性;不同病理分期的肺癌患者血小板增多率与病理分期相关，病理分期越晚，血小板增多率越高（P〈0．05），以Ⅳ型肺癌的发生率最高，占41．8％；肺癌患者有转移者血小板增多率35．5％比无转移者血小板增多率22．0％明显升高（P〈0．05）；肺癌化疗患者无效组血小板增多率41．7％较有效组27．8％高，两组比较差异具有显著性（P〈0．05）。【结论】肺癌患者外周血血小板计数增多与患者年龄、临床分期以及肿瘤转移之间具有明显的相关性，且外周血血小板计数与临床疗效有相关性，血小板增多可作为一个不良预后因素。观察肺癌患者的血小板计数可作为肺癌诊治及预后评估的辅助判断指标。
[Objective] To investigate the correlation between peripheral blood platelet count and clinical effect in patients with lung cancer.[Methods]ncer patients were enrolled in the study. The patients according to their ages were divided into ： 24 cases between 31-39, 153 cases between 40-49, 222 patients between 50-59 and 297 cases over the age of 60.According to the histological type they were divided into 280 cases of squamous cell carcinoma, 203 cases of adenocarcinoma, 151 cases of small cell carcinoma, 62 cases of undifferentiated carcinoma.According to the clinical pathological staging , the patients were divided into 43 cases of stage Ⅰ＋Ⅱ, 64 cases of Ⅲa, 412 cases of Ⅲb and 177 cases of stage Ⅳ.According to whether metastasis occurred or not ,the patients were divided into the group with metastasis of 451 cases and 245 cases as the non metastasis group. Furthermore,the patients were divided into the effective group of 561 cases and ineffective group （135 cases） according to the clinical curative effect concerned.The distribution of platelet increase rate among all the groups were compared.[Results] The incidence of thrombocytosis in patients with lung cancer was 30.75%. Patients with thrombocytosis of lung cancer were mainly in the elderly patients. Thrombocytosis rate in different age groups showed significant differences （ P 〈0.05）, and the comparesion of different histological types herewith had no significant difference;The increase rate of platelet in patients with lung cancer was related with pathological staging. The later pathologically staged, the higher thrombocytosis rate was （ P 〈0.05）, among which the IV type of lung cancer owned the highest incidence accounted for 41.8 % ;The increase rate of thrombocytosis of lung cancer patients with Metastasis was 35.5%, significantly higher than those without metastasis 22% （P〈 0.05） ;The increase rate of platelet in patients without chemotherapy efficacy was 41.7 %, higher than that of effective group 27.8%, the difference between the two groups was significant （ P 〈0.05）.[Conclusion]The increasement of peripheral blood platelet counts of lung cancer patients has a clear correlation with age, clinical stage and tumor metastasis, and peripheral blood platelet count is associated with clinical efficacy. The increased platelet count may be considered as an adverse prognostic factor. Observation of the platelet count in patients with lung cancer can be used as a supplementary indicator of lung cancer diagnosis and treatment as well as prognosis evaluation.
出处
《医学临床研究》
CAS
2015年第12期2349-2352,共4页
Journal of Clinical Research
基金
湖南省科技厅课题（NO.2011SK3172）
关键词
肺肿瘤/病理学
血小板计数
肿瘤分期
肿瘤转移
预后
Lung Neoplasms/PA
Platelet Count
Neoplasm Staging
Neoplasm Metastasis
Prognosis
